# The Main Pharmaceutical Inspectorate

Report No: GIF-IW-400/0493 01 01/04/36-1/16

# STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer <sup>1</sup>

#### Part 1

Issued following an inspection in accordance with:

Art. 111(7) of Directive 2001/83/EC as amended

The competent authority of Poland confirms the following:

The manufacturer: Chengdu Okay Pharmaceutical Co. Ltd.

Site address: No. 15 Chuangye Road Lingiong Industrial Zone, Qionglai, Sichuan Province, 611530,

China

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2015-10-28**, it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

• The principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC.

Online EudraGMP, Ref key: 33815 Issuance Date: 2016-02-19 Signatory: Confidential Page 1 of 3

<sup>&</sup>lt;sup>1</sup> The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and 80(7) of Directive 2001/82/EC, as amended, shall also be required for imports coming from third countries into a Member State.

### Part 2

## 1 NON-COMPLIANT MANUFACTURING OPERATIONS

Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary;

1.4	Other products or manufacturing activity	
	1.4.1 Manufacture of	
	1.4.1.4 Other: active substance(en)	

Manufacture of active substance. Names of substances subject to non-compliant:


# DIOSMIN(en)/DIOSMINA(pl)

# 3. NON-COMPLIANT MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : DIOSMIN

Active Substance . Diosiviny		
3.1	Manufacture of Active Substance by Chemical Synthesis	
	3.1.2 Manufacture of crude active substance	
	3.1.3 Salt formation / Purification steps :	
	crystallization	
3.5	General Finishing Steps	
	3.5.1 Physical processing steps :	
	drying, pulverization, blending	
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material	
	which is in direct contact with the substance)	
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging	
	material or container. This also includes any labelling of the material which could be used for	
	identification or traceability (lot numbering) of the active substance)	
3.6	Quality Control Testing	
	3.6.1 Physical / Chemical testing	
	3.6.2 Microbiological testing excluding sterility testing	

## Part 3



#### 1. Nature of non-compliance:

Overall, 21 deficiencies were observed during the inspection, including 5 critical and 10 major deficiencies. The critical deficiencies were observed in QC Dept. including calculation of impurities of Diosmin and there were no records of standard (used as a reference) for testing in-house standard. Also the data integrity was not guaranteed. In manufacturing Dept. presented measuring methods were inadequate to the results. The condition in clean area was not acceptable for final product. Critical deficiences: Testing of the final product: There was incorrectly way of calculation the impurities and Diosmin content. There were no records of prepared in-house HPLC standard. There was no confirmation of the conditions HPLC analysis. Computerized systems - documentation and control: There was found in HPLC system that the method was changed, without any savings of previous method. There were no logins and passwords to the HPLC system and no procedure for granting permission to access to the HPLC system. There was no register of persons autorized to access to to the HPLC system. On the same computer station there were two different HPLC software. Manufacturing documentation: Presented measuring methods of pH during the inspection time were inadequate to the results recorded in the batch report. Premises: Crude Diosmin drying was carried out in an area which did not provide the appriopriate coditions during the discharge from the dryer. Qualification of equipment: Some data of HVAC system qualification had been falsified. The major deficiencies were observed among others: in the warehouse, in the manufacturing documentation and in the production area.

### Action taken/proposed by the NCA

#### Recall of batches already released

It is recommended to perform a comlete analysis of the substance by manufacturer of medicinal products.

#### **Additional comments**

The inspection was performed by reques of API importer.

2016-02-19

Name and signature of the authorised person of the Competent Authority of Poland

Confidential

The Main Pharmaceutical Inspectorate

Tel: *Confidential* Fax: *Confidential* 

Online EudraGMP, Ref key: 33815 Issuance Date: 2016-02-19 Signatory: Confidential Page 3